CO6351811A2 - La proteina de tuberculosis rv2386c, composiciones y usos de la misma - Google Patents

La proteina de tuberculosis rv2386c, composiciones y usos de la misma

Info

Publication number
CO6351811A2
CO6351811A2 CO11009237A CO11009237A CO6351811A2 CO 6351811 A2 CO6351811 A2 CO 6351811A2 CO 11009237 A CO11009237 A CO 11009237A CO 11009237 A CO11009237 A CO 11009237A CO 6351811 A2 CO6351811 A2 CO 6351811A2
Authority
CO
Colombia
Prior art keywords
rv2386c
compositions
same
tuberculosis protein
protein sequence
Prior art date
Application number
CO11009237A
Other languages
English (en)
Inventor
James E Brown
Pascal Mettens
Dennis Murphy
Original Assignee
Glaxosmithkline Biolog Sa
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa, Glaxo Group Ltd filed Critical Glaxosmithkline Biolog Sa
Publication of CO6351811A2 publication Critical patent/CO6351811A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)

Abstract

La presente invención se refiere a un polipéptido que comprende: (i) una secuencia de proteína de Rv2386c; (ii) una variante de una secuencia da proteína de Rv2386c; o (iii) un fragmento inmunogónico de una secuencia de proteína de Rv2386c. En otros aspectos, la invención se refiere a los polinucleótidos, a las proteínas de fusión, y a los métodos asociados, para el tratamiento o la prevención de tuberculosis.
CO11009237A 2008-07-25 2011-01-27 La proteina de tuberculosis rv2386c, composiciones y usos de la misma CO6351811A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8369908P 2008-07-25 2008-07-25

Publications (1)

Publication Number Publication Date
CO6351811A2 true CO6351811A2 (es) 2011-12-20

Family

ID=41227131

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11009237A CO6351811A2 (es) 2008-07-25 2011-01-27 La proteina de tuberculosis rv2386c, composiciones y usos de la misma

Country Status (23)

Country Link
US (4) US20110206712A1 (es)
EP (1) EP2315834B1 (es)
JP (2) JP5981138B2 (es)
KR (1) KR20110049834A (es)
CN (2) CN106866801A (es)
AU (1) AU2009273132B2 (es)
BR (1) BRPI0916704A2 (es)
CA (1) CA2731547C (es)
CO (1) CO6351811A2 (es)
CY (1) CY1121632T1 (es)
DK (1) DK2315834T3 (es)
EA (1) EA201100070A1 (es)
ES (1) ES2685498T3 (es)
HR (1) HRP20181353T1 (es)
HU (1) HUE039159T2 (es)
IL (1) IL210589A (es)
LT (1) LT2315834T (es)
MX (1) MX2011000982A (es)
PL (1) PL2315834T3 (es)
PT (1) PT2315834T (es)
SI (1) SI2315834T1 (es)
UA (1) UA107329C2 (es)
WO (1) WO2010010179A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0708865A8 (pt) * 2006-03-14 2019-01-22 Univ Oregon Health & Science métodos para produzir uma resposta imune à tuberculose
WO2009158284A2 (en) 2008-06-26 2009-12-30 Mayo Foundation For Medical Education And Research Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
SG10201505149WA (en) * 2008-07-25 2015-07-30 Glaxosmithkline Biolog Sa Novel compositions and methods
CA2731547C (en) * 2008-07-25 2019-04-30 Glaxo Group Limited The tuberculosis rv2386c protein, compositions and uses thereof
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
US20140349320A1 (en) * 2011-12-15 2014-11-27 The Trustees Of The University Of Pennsylvania Using Adaptive Immunity to Detect Drug Resistance
CN107478849B (zh) * 2013-05-31 2019-08-20 中国医学科学院病原生物学研究所 用于结核病诊断和预防的蛋白
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN107110862B (zh) * 2014-08-15 2021-03-16 牛津免疫科技有限公司 结核分枝杆菌蛋白
CN105572352B (zh) * 2016-02-17 2017-07-28 遵义医学院附属医院 一组结核潜伏感染诊断标志物及其用途
WO2018104313A1 (en) 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Novel process
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
CN108950031A (zh) * 2018-06-29 2018-12-07 周琳 结核分枝杆菌的利福平耐药性诊断标志物及其应用
CN108866213A (zh) * 2018-06-29 2018-11-23 周琳 结核分枝杆菌利福平耐药性诊断标志物及其应用
CN109234414B (zh) * 2018-06-29 2022-05-17 周琳 结核分枝杆菌的对氨基水杨酸耐药性诊断标志物及其应用
CA3142300A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
EP3983011A1 (en) * 2019-06-14 2022-04-20 Statens Serum Institut Fusion proteins for tuberculosis vaccines
CN112457410B (zh) * 2020-11-05 2023-04-07 迈克生物股份有限公司 用于结核分枝杆菌感染检测的抗原组合物
DE202022102137U1 (de) 2022-04-21 2022-04-28 Damayanthi Dalu Eine neue Zusammensetzung zur Behandlung von Tuberkulose
CN115725607B (zh) * 2022-07-14 2023-11-28 山东第一医科大学附属省立医院(山东省立医院) 一种鼻疽诺卡菌的致病靶基因及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK279188B6 (sk) 1992-06-25 1998-07-08 Smithkline Beecham Biologicals S.A. Vakcínová kompozícia spôsob jej prípravy a použiti
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US7087713B2 (en) 2000-02-25 2006-08-08 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US6613881B1 (en) 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
CN1163602C (zh) 1998-04-07 2004-08-25 科里克萨公司 结核杆菌抗原融合蛋白及其应用
DE60139963D1 (de) 2000-06-20 2009-10-29 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
WO2002074903A2 (en) 2001-02-22 2002-09-26 Institut Pasteur Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
US20030236393A1 (en) 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
KR101178776B1 (ko) 2004-02-06 2012-09-07 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 치료학적 잠재성을 가진 어드헤신 및 어드헤신계 단백질을 동정하기 위한 컴퓨터 장치
NZ562729A (en) * 2005-04-29 2009-10-30 Infectious Disease Res Inst Id Novel method for preventing or treating M tuberculosis infection using Mtb72f fusion proteins
WO2008007942A1 (en) 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
US20100055166A1 (en) 2007-03-02 2010-03-04 Gerald Hermann Voss Novel method and compositions
SG10201505149WA (en) 2008-07-25 2015-07-30 Glaxosmithkline Biolog Sa Novel compositions and methods
CA2731547C (en) * 2008-07-25 2019-04-30 Glaxo Group Limited The tuberculosis rv2386c protein, compositions and uses thereof
WO2010010178A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A The tuberculosis rv2707c protein, compositions and uses thereof
BRPI0916703A2 (pt) 2008-07-25 2019-12-24 Glaxo Group Ltd usos de um polipeptídeo, e de um polinucleotídeo, e, composição
BRPI1006452A2 (pt) 2009-04-24 2016-12-27 Statens Seruminstitut vacina ou composição imunogênica que é administrada após a exposição a indivíduos com infecção latente que previne a reativação de tuberculose; método para tratar um animal, incluindo o ser humano, contra a reativação da infecção por tuberculose causada por micobactérias virulentas, uso de um antígeno selecionado do grupo
WO2010132112A2 (en) 2009-05-14 2010-11-18 Wisconsin Alumni Research Foundation Immunogenic compositions against tuberculosis
EP2528621B1 (en) 2010-01-27 2016-09-21 GlaxoSmithKline Biologicals S.A. Modified tuberculosis antigens

Also Published As

Publication number Publication date
KR20110049834A (ko) 2011-05-12
US20140314802A1 (en) 2014-10-23
IL210589A (en) 2015-05-31
ES2685498T3 (es) 2018-10-09
US9480735B2 (en) 2016-11-01
BRPI0916704A2 (pt) 2020-08-18
CA2731547A1 (en) 2010-01-28
AU2009273132A1 (en) 2010-01-28
CN106866801A (zh) 2017-06-20
US20170065697A1 (en) 2017-03-09
AU2009273132B2 (en) 2015-09-03
US10286053B2 (en) 2019-05-14
IL210589A0 (en) 2011-03-31
CA2731547C (en) 2019-04-30
EP2315834B1 (en) 2018-06-13
DK2315834T3 (en) 2018-08-20
LT2315834T (lt) 2018-09-10
PL2315834T3 (pl) 2018-12-31
WO2010010179A1 (en) 2010-01-28
CY1121632T1 (el) 2020-07-31
EP2315834A1 (en) 2011-05-04
UA107329C2 (uk) 2014-12-25
HRP20181353T1 (hr) 2018-10-19
JP2011528896A (ja) 2011-12-01
JP6104326B2 (ja) 2017-03-29
HUE039159T2 (hu) 2018-12-28
PT2315834T (pt) 2018-08-10
JP5981138B2 (ja) 2016-08-31
CN102165064B (zh) 2017-06-20
CN102165064A (zh) 2011-08-24
EA201100070A1 (ru) 2011-10-31
JP2016000734A (ja) 2016-01-07
MX2011000982A (es) 2011-03-02
SI2315834T1 (sl) 2018-09-28
US20140086948A1 (en) 2014-03-27
US20110206712A1 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
CO6351811A2 (es) La proteina de tuberculosis rv2386c, composiciones y usos de la misma
CO6400198A2 (es) Composiciones y metodos novedosos
CO6341637A2 (es) \\\\\\\"composiciones y metodos novedosos\\\\\\\"
CR11580A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
CL2020000428A1 (es) Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana.
UY33204A (es) Metodos y composiciones usando polipeptidos de fusion de fgf23
CL2010001426A1 (es) Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas.
PE20142451A1 (es) Composiciones de conjugados de xten y metodos para realizar las mismas
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
CL2010001569A1 (es) Pestivirus atenuado mediante la mutacion conjunta de las proteinas e erns y n pro.composicion inmunogenica y vacuna que lo comprende, metodo para atenuar pestivirus basado en la supresion de la dimerizacion de la proteina e rns y la ianactivacion de la proteina n pro.
BRPI0508421A (pt) sistemas de transporte biológico de múltiplos componentes
EA201171494A1 (ru) Миметики белка smac
GT200900163A (es) Nuevos compuestos y sus efectos sobre el conductismo de la alimentacion.
BRPI0715396B8 (pt) método de produção de uma composição para vacina
CL2008000910A1 (es) Proteina de fusion que comprende una proteina que corta el peptido beta amiloide; composicion farmaceutica que la comprende, y su uso para prevenir y/o tratar enfermedades relacionadas con el peptido beta amiloide.
BRPI0606687A2 (pt) composições nutracêuticas
BRPI0819092A2 (pt) Evolução direcionada usando proteínas que compreendem aminoácidos não naturais.
AR083126A1 (es) Composicion vacunal para el control de las infestaciones por ectoparasitos
ECSP10010211A (es) Composición
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
CL2009001083A1 (es) Variantes de receptores de la proteina c3 de complemento (crig), molecula quimerica y composicion farmaceutica que las comprende; uso de las variantes para preparar un medicamento para prevenir o tratar una enfermedad asociada al complemento, tal como una enfermedad inflamatoria o autoinmune.
AR076892A1 (es) Conjugados de albumina-peptido amiloide y usos de los mismos
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas
AR104952A1 (es) Bioconjugados y usos de los mismos
BRPI0506041A (pt) proteìna indutora de angiogênese acelerada, composições indutoras de angiogênese acelerada e usos de proteìna indutora de angiogênese acelerada

Legal Events

Date Code Title Description
FC Application refused